Resistance mutations in HIV-infected patients experiencing early failure with nelfinavir-containing triple combinations

Medical Science Monitor

Volumn 8, Issue 9, 2002, Pages

  Núńez, Marina ^a   De Mendoza, Carmen ^a   Valer, Luisa ^a   Casas, Esperanza ^a   López Calvo, Soledad ^a   Castro, Ángeles ^a   Rosón, Beatriz ^a   Podzamczer, Daniel ^a   Rubio, Amalia ^a   Berenguer, Juan ^a   Soriano, Vincent ^a  

^a NONE   (Spain)

Author keywords

Drug resistance; Nelfinavir; Protease inhibitor; Treatment failure

Indexed keywords

LAMIVUDINE; NEVIRAPINE; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; VIRUS RNA;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG SENSITIVITY; FEMALE; GENE SEQUENCE; GENETIC ANALYSIS; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MULTIDRUG RESISTANCE; POLYMERASE CHAIN REACTION;

ADULT; DRUG RESISTANCE; FEMALE; GENES, VIRAL; GENOTYPE; HIV; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV SEROPOSITIVITY; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MALE; MIDDLE AGED; MUTATION; NELFINAVIR;

EID: 3242892511     PISSN: 12341010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Hogg R, Heath K, Yip B et al: Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA, 1998; 279: 450-454
2. Gulick R, Mellors J, Havlir D et al: Treatment with indinavir, zidovudine, and lamivudine in adults with HIV infection and prior antiretroviral therapy. N Engl J Med, 1997; 337: 734-739
3. Deeks S, Hecht F, Swanson M et al: HIV-RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. AIDS, 1999;13:35-43
4. Paredes R, Mocroft A, Kirk O et al: Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe; results from the EuroSIDA study. Arch Intern Med, 2000; 160: 1123-1132
5. Hirsch M, Brun-Vezinet F, D'Aquila R et al: Antiretroviral drug resistance testing in adult HIV-1 infection. JAMA, 2000; 283: 2417-2426
6. Race E, Dam E, Obry V et al: Analysis of HIV cross-resistance to protease inhibitors using a rapid single-cycle recombinant virus assay for patients failing on combination therapies. AIDS, 1999; 13: 2061-2068
7. Soriano V: Sequencing antiretroviral drugs. AIDS, 2001; 15: 547-551
8. Tebas P, Patick A, Kane E et al: Virologic responses to a ritonavir-saquinavir-containing regimen in patients who have previously failed nelfinavir. AIDS, 1999; 13: 23-28
9. Collins M, Irvine B, Tyner D et al: A branched DNA signal amplification assay for quantitation of nucleic acid targets below 100 mole cules/ml. Nucleic Acids Res, 1997; 25: 2979-2984
10. Schinazi R, Larder B, Mellors J: Mutations in retroviral genes associated with drug resistance: 2000-2001 update. Intern Antiviral News, 2000; 8: 65-89
11. Gallant J: Strategies for long-term success in the treatment of HIV infection. JAMA, 2000; 283: 1329-1334
12. Descamps D, Flandre P, Calvez V et al: Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. JAMA, 2000; 283: 205-211
13. Havlir D, Hellmann N, Petropoulos C et al: Drug susceptibility on HIV infection after viral rebounds in patients receiving indinavir-containing regimens. JAMA, 2000; 283: 229-234
14. Mouroux M, Yvon-Groussin A, Peytavin G et al: Early virological failure in naive HIV patients receiving saquinavir (soft gel capsule)stavudine-zalcitabine (MIKADO trial) is not associated with mutations conferring viral resistance. J Clin Microbiol, 2000; 38: 2726-2730
15. Condra J, Holder D, Schleif W et al: Genetic correlates of virological response to an indinavir-containiug salvage regimen in patients with nelfinavir failure. 3th International Workshop on HIV Drug resistance & Treament Strategies. San Diego, 1999; [Abstract 63]
16. Zolopa A, Shafer R, Warford A et al: HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed. Ann Intern Med, 1999; 131: 813-821
17. Yerly S, Rickenbach M, Popescu M et al: Drug resistance mutations in patients initiating protease inhibitors-containing HAART with either nelfinavir or indinavir in a population-based cohort. Antiviral Therapy, 2001; 6: 13
18. Martinez-Picado J, Savara A, Sutton L, D'Aquila R: Replicative fitness of protease inhibitor-resistant mutants of HIV type 1. J Virol, 1999; 73: 3744-3752
19. Wrin T, Gamarnik A, Paxinos E et al: Measuring the replicative fitness of recombinant HIV-1 vectors expressing protease and reverse transcriptase derived from patient viruses. 7th CROI; Chicago, 2000; [Abstract 233]
20. Kemper C, Witt M, Keiser P et al: Sequencing of protease inhibitor therapy: insights from an analysis of HIV phenotypic resistance in patients failing protease inhibitors. AIDS, 2001; 15: 609-615